INTRODUCTION
Publication of the mathematics of accumulation in the one-compartment open model by Widmark and Tandberg (1) and the two papers on the twocompartment open model by the organizer of this conference, Professor Torsten Teorell (2, 3) , were the origins of pharmacokineties. Many of us who have studied the literature of pharmacokinetics have been amazed at the insight and foresight embodied in Professor Teorell's two papers. The classical one-and two-compartment open linear models have withstood the test of time, have achieved accurate assessment of rates of absorption, metabolism, and excretion when applied to certain specific drugs, and have been very useful for predictive purposes. Undoubtedly in the future these classical models will continue to be as useful as they have in the the past. These classical pharmacokinetics models are based on systems of linear differential equations, which may conveniently be integrated by the use of Laplace transforms. Kinetic linearity was defined by Kriiger-Thiemer (4) as direct proportionality of transfer rates to concentrations or concentration differences.
A modern view of pharmacokinetics must include both linear and nonlinear systems. For many years in the linear pharmacokinetic area authors spent a great deal of time and journal space deriving the equations they needed to interpret data. Recently, Benet and Turi (5) and Benet (6) made significant contributions in the linear pharmacokinetic area. The Benet method (6) allows one to write the Laplace transform for the amount of drug in any compartment of a mammillary model and to obtain the inverse Laplace transform (i.e., the final integrated equation) consisting of a sum of exponential terms. The method is highly recommended for those not familiar with the technique. Since Dr. Garrett has reviewed classical pharmacokinetics, I will spend most of my time comparing linear and nonlinear pharmacokinetics and discussing nonlinear pharmacokinetics.
HISTORICAL
Evidence of nonlinearities in pharmacokinetics goes back almost as far as the theory of linear pharmacokinetics. Widmark (7, 8) in the early 1930s originated the concept that ethyl alcohol is eliminated at a fixed rate independent of its concentration in the body. After an oral dose of ethyl alcohol, a certain range of alcohol blood concentrations appear to give a straight line when the data are plotted on cartesian coordinate graph paper, but a line with concave decreasing curvature when plotted on semilogarithmic graph paper. Although Widmark's concept is still widely accepted and taught, it is really incorrect, as discussed in a paper by Wagner and Patel (9) .
In performing the literature search for this review, I was rather amazed to find in my files over 160 articles which contained evidence of nonlinearities in drug absorption, distribution, metabolism, and excretion, and in the pharmacokinetics of drug action. This review is not intended to be an exhaustive search. In the area of pharmacokinetics of drug action, only reviews, and not original literature, are cited. Much of the literature has been summarized in a series of tables. Table 1 lists the evidence for nonlinearities in drug absorption, Table II the evidence for nonlinearities in drug distribution, Table III the evidence for nonlinearities in drug metabolism, Table IV the evidence for nonlinearities in renal excretion of drugs and metabolites, Table V the evidence for nonlinearities in biliary excretion of drugs, and 
COMPARISON OF LINEAR AND NONLINEAR PHARMACOKINETICS

Drug Absorption
In linear pharmacokinetics, the process of drug absorption has usually been described mathematically by one or two first-order processes. KrfigerThiemer (4,140,141) stated that deviations from linear drug absorption kinetics may result from low solubility of the drug, from a low rate of dissolution, from many different types of sustained release preparations, and from saturable active absorption processes. In addition, one may add the following : fluctuations and changes in intestinal blood flow rate, as result of the work of Ochsenfahrt and Winne (13), Crouthamel et al. (20) , and Winne (21); the change in pH of luminal contents as a basic, acidic, or amphoteric drug moves down the gastrointestinal tract, as the result of the work of Shore et al. (142) and Hogben et al. (143) and the theoretical papers of Suzuki et al. (19, 144) and Wagner and Sedman (27) ; and the possible effects of binding of drugs to mucosal tissue, as a result of the work of Kakemi et al. (18) , Dearden and Tomlinson (24) , and Fuwa et al. (25) . Delay in gastric emptying, such as caused by food in the stomach, enteric-coated tablets, sustained-release preparations, anticholinergic agents, etc., will also cause nonlinearities in the absorption process. The work of Rowland et al. (14) with griseofulvin in man illustrates, that administration of even a micronized drug powder yields absorption data which cannot be fitted well by simple first-order kinetics. 
Metabolism and Active Tubular Secretion in the Kidney
Vr,, Km+C
It is the relative values of K m and C which determine whether the MichaelisMenten equation should be "'collapsed" to a zero-order or first-order rate expression. The fundamental assumptions behind linear pharmacokinetics are that (a) saturable rate processes may be "collapsed" to first-order rate equations, and (b) saturable binding processes may be "'collapsed" to the equation of a straight line. In actual practice, these both involve the approximation of a segment of a gently curving line by a straight line. The data in Table VII , calculated using equation 1 and literature values of K,~, suggest that the Michaelis-Menten equation should not be "'collapsed" to a zeroorder rate expression at least for salicylate, blood alcohol, and diphenylhydantoin. The computer simulation of salicylate urinary excretion data by Levy et al. (80) , the computer fitting of whole capillary blood alcohol concentrations by Wagner and Patel (9), and the plasma diphenylhydantoin concentration data by Gerber and Wagner (108) support this statement. The estimation of the V m and Km of the Michaelis-Menten equation from blood concentration or urinary excretion data is about as easy with a modern computer as the estimation of a first-order rate constant. Since the K,, and Vm values obtained will usually provide an adequate description of the kinetics at all dose levels, pharmacokineticists in the future may wish to use this approach rather than report a series of rate constants or half-lives of elimination which vary with the dose administered.
Uptake of Drug by Tissues
Figure 2 compares linear and nonlinear pharmacokinetics with respect to the uptake of drugs by tissues. At the top is the theoretical prediction of the amount of drug in the tissues as a function of dose for the two-compartment open model with rapid intravenous injection. The appropriate equation from which the lines were drawn is shown inset in the figure. The model predicts that the amount of drug in tissues, A2, will be a linear function of dose administered, for a fixed value of time, t. The types of curves one expects in nonlinear pharmacokinetics is indicated at the bottom of the figure. The asymptotic nature of the curves results from the assumption that there is a limiting amount of drug that can be taken up by the tissues. This appears reasonable since there is obviously only a certain amount of each kind of tissue in the body. The curves shown in Fig. 2 were generated as follows: Values of A = 10, B = 1, and K = 2.75 were assigned, and equation 2 of Figure 5 shows the lung (at the top) and heart (at the bottom) concentration data as a function of dose. It is noteworthy that these data show the nonlinear asymptotic curvature analogous to the curves generated with the simulation example shown in Fig. 2 .
TOTAL IN / ~' / 4 TISSUES '/AfI
Methylene blue is completely ionized at physiological pH values and hence is analogous to a quaternary ammonium compound. Diphenhydramine is a typical weakly basic amine. Both of these drugs were taken up by tissues extremely rapidly; with diphenhydramine, the tissue concentration measured l rain after injection was usually the highest concentration observed. With methylene blue, an average of 27% of the dose (range 20-32 %) was accounted for in only four tissues (liver, kidney, heart, and lung) 3 rain after the intravenous dose. Currently Theodore Benya, one of my graduate students, is studying the tissue distribution of warfarin, an acidic drug, in the rat. The same picture is emerging. After intravenous injection, the uptake of warfarin in tissues is extremely rapid and the disappearance exceedingly slow. The general picture emerging from these studies is that tissue uptake of drug is extremely rapid--much more rapid than one would usually predict from two-compartment analysis--and liberation of the tissue-bound drug is a slow process. Kinetic nonlinearity is very evident. The often repeated statement that highly plasma protein-bound drugs do not get into tissues is apparently incorrect since warfarin is about 97 ~o bound to plasma proteins.
~Wagner A CURRENT AND FUTURE PROBLEM IN PHARMACOKINETICS
It is exceedingly difficult, if not impossible, to determine if a given set of whole blood, plasma, or serum concentrations of a drug measured after one dose is best described by a classical linear or nonlinear mathematical model. The problem is even more difficult with urinary data. Obtaining data after only one or two doses of a drug is usually insufficient to deduce the appropriate model. It is feasible for known nonlinear data to appear to be linear pharmacokinetic data when only one dose of a drug is studied. This is so even when the drug is administered by rapid intravenous injection. This concept is illustrated by two simulations below.
Example 1
The data points in where ~ > fl (6) in the indicated ranges are the model-predicted concentrations for the twocompartment open model. The dotted line in the figure is the extrapolated two-compartment model prediction. The points deviate from the line beyond 9 hr. However, if these were real data, and if one only had an assay sensitive to 0.05 pg/ml, then one could not decide on these basis of these data only whether equation 3 or equations 5 and 6 were the appropriate mathematical mode]. This example was published by DiSanto and Wagner (148) . If data were available from several simulations with different C o values (or real data were available following administration of several different doses), then a distinction between linear and nonlinear pharmacokinetics could be made.
Example 2
The data points for curve A of Fig. 7 are the same as those in Example 1 and Fig. 6 . However, in Fig. 7 the least-squares log Ct line was drawn through the points in the 5-to 9-hr time region. The dotted line indicates the extrapolation of the least-squares line. Hence only terminal points, in somewhat less than one log cycle, were linear on the semilogarithmic graph paper. The data points for curve B of Fig. 7 were obtained by numerical integration of logarithmic graph paper. Langmuir-type tissue binding causes convex decreasing curvature when the C,t data are plotted on semilogarithmic graph paper. A judicious mixture of Michaelis-Menten elimination kinetics and Langmuir-type tissue binding (i.e., the parameters are in a certain "space") yields the result shown as line B in Fig. 7 . In a modern view of pharmacokinetics, we must be aware that such things can happen and, perhaps, not be as sure as we have in the past that fitting data to a model proves that the model is correct.
Three "real-world" examples along the same lines will be discussed.
Salicylate
As indicated in Table III , Schachter and Manis (69) published evidence of saturation effects in the formation and active tubular secretion of salicylurate and salicyl phenolic glucuronide from salicylate following an oral dose of 4 g of sodium salicylate in man. They also reported evidence of active tubular secretion of salicylate and salicyl acyl glucuronide. During the period 1965-1972, Dr. Levy, who is with us today, intensively studied the aspirin-salicylate problem (see citations in Table III under salicylic acid). He tackled the problem many ways and has certainly shown, at least to my satisfaction, that one must use Michaelis-Menten kinetics to elucidate the formation of salicylurate and salicyl phenolic glucuronide from salicylate. Rowland and Riegelman (149) and Rowland et al. (150) evaluated the pharmacokinetics of acetylsalicylic acid in man following intravenous administration by means of the classical two-compartment model for a drug and its metabolite. Wagner (151) showed that approximately 50% of a metabolite excreted in the urine may be excreted at such rates that the cumulative urinary excretion plot would appear to be nearly linear when the model is a catenary chain with parallel paths involving only first-order rate constants. In a review as late as 1968, Wagner (152) supported the firstorder elimination kinetics of salicylate. However, currently I agree with Dr. Levy's interpretation. It was undoubtedly Dr. Levy's and Dr. KrtigerThiemer's papers which first stimulated my interest in nonlinear pharmacokinetics. I am sure we have all learned a great deal from the saga of salicylate. In case the point is lost, I wish to reiterate that individual sets of nonlinear data can be fitted by linear pharmacokinetic equations and therein lies the real problem.
Diphenylhydantoin
Dayton et aI. (92) published data which indicated that the elimination half-life of diphenylhydantoin in the dog apparently increased when the dose was raised from 20 to 50 mg/kg. Analysis of diphenylhydantoin plasma concentration data, obtained following intravenous administration to man, by Suzuki et al. (103) and Blum et al. (104) indicated that dose-dependent kinetics did not occur. Plasma concentration data obtained following oral administration of diphenylhydantoin to man, published by Arnold and Gerber (105) , indicated that dose-dependent kinetics did occur. Studies in mice (106) and in rats (107) also indicated marked nonlinearity. Recently, Gerber and Wagner (108) fitted sets of diphenylhydantoin plasma concentration data in man, and whole blood diphenylhydantoin concentration data in the rat, to the integrated form of the Michaelis-Menten equation :
Although evaluated by the authors according to first-order kinetics, the diphenylhydantoin plasma concentration data of Glazko et al. (102) 
Riboflavin in the Rat
Axelson and Gibaldi (133) discussed an unusual example of nonlinear pharmacokinetics. Estimation of the availability of riboflavin-Y-phosphate after oral administration to the rat is greatly complicated because of the occurrence of a complex and markedly nonlinear dose-dependent excretion of the vitamin. The elimination of the vitamin involves at least two nonlinear processes occurring simultaneously and having opposite ~ffects on the dose-total urinary recovery relationship. One process involves biliary excretion which increases disproportionately with increasing body levels of riboflavin. The other process appears to be a binding of the vitamin to tissues which function kinetically as deep compartments. Apparently, the higher the body level of the vitamin, the smaller the fraction that can be "immobililized'" in the compartment and the larger the fraction that can be detected in the urine. The latter is another way of stating in words what is implied by equation 4. 6. Administer the drug on a multiple dose regimen at several dose levels, establish an equilibrium state, then measure the metabolite concentration in the whole blood or plasma in a dosage interval at the equilibrium state. If the areas under the metabolite concentration curves at the equilibrium state are not a linear function of dose, but rather a curvilinear function of dose, then this is excellent evidence for the operation of Michaelis-Menten kinetics in the formation of the metabolite. One must be careful to insure that excretion is rate-limited by formation of the metabolite and that one is not dealing with a case such as acetaminophen, where the formation step of conjugation proceeds much more rapidly than the subsequent excretion step (124) .
NONLINEAR MODELS AND THE FITTING OF-DATA
Plasma Protein Binding
The effects of plasma protein binding of drugs on drug distribution and elimination are still controversial. One type of deviation from first-order elimination kinetics from the human body is characterized by a diminishing steepness of the slope of the total plasma concentration vs. time curve on semilogarithmic graph paper (i.e., convex decreasing curvature). This type of deviation exists for some sulfonamides which show a high degree of binding to plasma proteins and was discussed and referenced by Krtiger-Thiemer (4). The higher the affinity for protein binding, the greater will be the bending of the log concentration vs. time curve. This is just the opposite behavior to that Martin (153) predicted from a judgment of the same problem. Krtiger-Thiemer (4) published a mathematical model which could explain such deviations. In the conclusion of a review on the binding of drugs by plasma proteins, Meyer and Guttman (154) stated:
An impression, gained from the literature, is that there appears to be a tendency to overemphasize the general importance of the binding phenomenon in the behavior of drugs in the body. Evidence exists that only in the case of highly bound agents wilt binding be important in a practical sense. Many workers, in attempting to extrapolate in vitro data to in vivo expectations, tend to lose sight of the fact that the plasma comprises a relatively small fraction of the total volume available for drug distribution and that protein~drug complexes of rather extraordinary stability must be formed to substantially reduce the amount of drug that exists in the body in the active, diffusible, unbound form. A number of important drugs do, however, fall in the category of "'strongly bound" and these serve as examples which emphasize the need to at least consider protein binding as a necessary parameter in the characterization of drug behavior.
Coffey et al. (155) described numerical methods for the solution of differential equations arising from nonlinear binding of drugs to plasma proteins, assuming one-and two-compartment pharmacokinetic models. The results suggested that binding of drugs to plasma proteins should cause detectable nonlinearity in the log C vs. t plot only if doses are sufficiently high to approach saturation of binding sites, or if the number of binding sites in plasma is small. The effect of competition for binding sites in plasma was also studied by the same authors. They reported: "It appears that, unless the tissue distribution volume is quite small, competition for binding sites would not be expected to have a large effect." Curry (156) also studied this problem, but his results are discussed under tissue binding.
During his lifetime, Dr. E. Krtiger-Thiemer contributed a great deal to pharmacokinetics. Only a few of his many papers are cited in this review (4, 140, 141, 157) , but the cited papers contain many references to his work. He was mainly concerned with the problem of accumulation of drugs, the pharmacokinetics of suitable dosage requirements for individual patients, and the establishment of sufficient plasma concentration of free (unbound) drug, once the parameters of binding of the specific drug to plasma proteins were known. He developed and applied many mathematical models to reach these objectives. He developed many digital computer programs to allow the fitting of observed data to a specific mathematical model.
For a 70-kg man, total plasma albumin is about 120 g and total interstitial albumin is about 156g (158) . Hence total body albumin is about 0.276 kg or about 0.4 ~o of body weight. If total body water is taken as 60 % of body weight, the "total tissue" expressed as dry weight is 28 kg or 40 % of body weight. Thus the ratio of total dry tissue mass to total albumin mass is about 100: 1. Since there are about 70 cardiac passes of blood per minute, and the dissociation of plasma protein-drug complexes, where it has been measured, is an exceeding rapid process, with a half-life of the order of 20 mseconds (159), it is not difficult to see that in most cases the binding of drugs to tissues will be kinetically much more important than the binding of drugs to albumin. This was pointed out also by Gillette (160) . It is perhaps fortuitous, but Wiegand and Chun (58), after studying the serum protein and tissue binding of erythromycin and erythromycin-2'-propionate ester, calculated that drug bound to serum proteins is only about 1 70 of the dose and that most of the drug is bound to tissues.
Tissue Binding
In the light of the discussion above, it is amazing that so little experimental investigation has been conducted on the measurement of tissue concentrations of drug as a jhnction of both time and dose. Most "distribution" data of specific drugs in animals and man have resulted from measurement of tissue concentrations at only one or two times after administration and usually following only one specific dose of drug. Such data give no insight into the kinetics of drug distribution. Recently, some investigators have measured tissue and plasma or whole blood concentrations as a function of tissue and dose. Drs. Bischoff and Dedrick, who reviewed other topics during this conference, have reported such data and developed pharmacokinetic models to explain such data. Dedrick and Bischoff (161) discussed pharmacokinetics in application to the artificial kidney: Bischoff and Dedrick (49) (41) . The flow-ratelimited model, described in that paper, incorporated compartments for the gastrointestinal tract, the liver and enterohepatic circulation, plasma, kidney, and muscle. Three compartments in series were used to simulate bile formation and secretion time in the liver. Transit of drug down the gastrointestinal tract was handled similarly, except that provision was made for transport through the intestinal wall. Tissue binding was assumed to be the sum of a linear nonspecific binding and a strong binding, presumed to be associated with dihydrofolate reductase, in conformity with equation 10:
The model predicted the time courses of methotrexate in luminal contents of small intestine, liver, kidney, muscle, and plasma of mice, rats, and dogs with reasonable accuracy. As part of the model for thiopental pharmacokinetics, Bischoff and Dedrick (49) used two-term equations, such as equation 11, to estimate the bound concentration, x, of thiopental in tissues and in plasma :
In equation 11, C represents the free (unbound) concentration of drug. Curry (156) reported that concentrations of chlorpromazine fluctuate in the plasma of dogs and man after intravenous doses. He examined the possibility that the fluctuations could arise from movement of the drug between tissue and plasma stores by performing simulations. His calculations showed that small changes in protein binding of drugs in plasma and tissues could cause redistribution of highly bound drugs between tissues and plasma. Also, redistribution would be greatest after changes in tissue binding of highly bound drugs. He hypothesized that fluctuations in chlorpromazine plasma concentrations could be caused this way.
A generalized nonlinear pharmacokinetic model was elaborated by DiSanto (163) and Wagner (147) . The model takes into account the nonlinear tissue binding of drug to one or more tissues associated with one or more fluid compartments. Dose-dependent metabolism or urinary excretion may be incorporated into the generalized model by replacing the first-order elimination constant by an expression of the Michaelis-Menten type. Several specific applications of the general theory were discussed. The chapter (147) contains 126 equations, hence is too extensive to be reviewed here. Equations 2 and 3, above, result from the simplest specific application of the generalized model and were employed by DiSanto and Wagner (148) in simulations and by DiSanto and Wagner (125) in interpreting whole blood concentrations obtained following rapid intravenous injection of five different doses of methylene blue in a dog. Figure 8 shows the results of a simultaneous fit of the whole blood concentration data, obtained following the five different doses of methylene blue, to equation 3 ; only one value of each of the parameters A, B, and K and five different C o values were estimated during the digital computer fitting with Dr. Metzler's program NONLIN, modified by addition of a rootfinder subroutine. It is feasible that such an approach, with the same or alternate mathematical models, may yield valuable information for studies in comparative pharmacology. In such a case, the number of parameters estimated is small, and comparison of the values obtained from one species of animal to another with those estimated from human data may be a useful clue as to the appropriate species of animal for long-term toxicological studies. (80) simulated the time courses of the urinary excretion rate of total salicylic acid and metabolites, salicyluric acid, salicyl acyl glucuronide, salicyl phenolic glucuronide, gentisic acid, and salicylic acid in four subjects following a 3-g oral dose of salicylic acid as sodium salicylate in aqueous solution. In order to do this, it was necessary to determine the values of 14 individually determined constants (79) . The formidable technical effort required an average of over 400 analyses per dose per subject. The constants estimated following the 3-g dose allowed excellent predictions following 1-and 0.19-g doses. The model equations employed involved Michaelis-Menten equations for the formation of salicylurate and salicyl phenolic glucuronide and first-order equations for formation of salicyl acyl glucuronide and gentisic acid and for excretion of unchanged salicylic acid and its absorption from the gut. Figure 9 is taken from the paper of Wagner and Patel (9) . The points are whole capillary blood ethanol concentrations measured in the same subject at different times. Two of the curves resulted from 60-ml, two of the curves resulted from 30-ml, and one curve resulted from 15-ml oral doses of 95 ~o ethyl alcohol. The solid lines drawn through the terminal points are the model-predicted values, based on fitting to equation 9 by numerically integrating the Michaelis-Menten equation on the digital computer and the assignment of equal weights. It was found in this study that the absorption rate of ethanol, and the values ofK m and V,,, varied widely in the same subject and apparently in a random manner not related to dose or time of administration. Figure 10 is taken from the paper of Gerber and Wagner (108) . It shows the fit of plasma concentrations of diphenylhydantoin in a human subject to equation 9. The data were collected starting 12 hr after the last dose when doses of 2.3, 4.7, and 7.9 mg/kg of sodium diphenylhydantoin (as Dilantin) were administered daily for 3 days during different time periods. The V,, value estimated was 0.253/~g/(ml x hr) and the K,, value estimated was 7.77/~g/ml.
Krfiger-Thiemer and Levine (141) discussed several non-first-order models of drug metabolism including one which incorporated both capacity limitation and restricted availability of substrate.
Miscellaneous Causes of Nonlinearities
As summarized in Tables I, IV, hepatic drug-metabolizing enzyme activity, as discussed by Civen et al. (164) and Radzialowski and Bousquet (165) , will undoubtedly cause nonlinearites even though we may not be able to "see" them readily. Enzyme stimulation and inhibition (166) 
Data Fitting Aids
The fitting shown in Fig. 10 was achieved by successive trials of numerical integration of the Michaelis-Menten equation by the Runge-Kutta method using a simple electronic calculator. This is analogous to the use of an analog computer and suffers from the fact that no standard deviations of the estimated parameters, or other mathematical and statistical information, are obtained along with the fitting. Usually one uses a high-speed digital computer with a suitable nonlinear least-squares estimation program. Dr. Berman's SAAM program, Dr. Metzler's NONLIN, and Control Data's MIMIC ate examples of successful programs which have been used widely for data-fitting and simulation purposes. Recently, Atkins (167,168) described a new versatile digital computer program for nonlinear regression analysis. The iteration procedure used in this program possesses two important advantages over those used in the past, namely that second partial derivatives need not be calculated and convergence is guaranteed. Quasilinearization, discussed by Buell and Kalaba (169) , may prove to be an aid in fitting of nonlinear models to e~'~perimental data.
Pooling of F~rallel Paths
If there are parallel first-order paths in classical linear pharmacokinetics, one can simply add the first-order rate constants to obtain the overall elimination rate constant. But can we pool parallel Michaelis-Menten paths and parallel Langmuir-type tissue binding equations justifiably? About a year ago, I gave this problem to one of my graduate students, Allen J. Sedman, and at the meeting of the A.Ph.A. Academy of Pharmaceutical Sciences in April 1972 we presented a paper entitled "Quantitative Pooling of Both Parallel Michaelis-Menten Formation Equations and Langmuir-Type Equations for Binding of Drugs to Tissues" (170) . In the paper, we answered the above question with a qualified "yes." Sedman developed equations which allowed calculation of the pooled parameters, V~p and K~p, from the microscopic parameters Vml, V,,2, K,,1, and Km2 for parallel MichaelisMenten paths and also for the Langmuir-type equations. The simulated data could always be fitted essentially exactly using the calculated pooled parameters. When the parameters have a certain relationship to each other, there is no problem in the sense that the pooled parameters need not change in dose. In certain cases, which are usually predictable, the pooled parameters will change with change in dose. The simulations suggested the appropriate experimentation with a given drug. One should study as low a dose as one can measure adequately and as high a dose as one may give safely, and see if the nonlinear parameters appear to change with dose. If they do not, then one is reasonably safe with the pooling concept within that dose range with that drug. In this rapidly moving field, one is never alone. When we returned from the Houston meeting, we found the paper by Spears et al. (171) and the paper of Neal (172) which treated the same problem, but in a different way than we tackled it.
SOME COMMENTS ABOUT MICHAELIS MENTEN KINETICS
In Wagner (109) and Wagner and Patel (9) , the properties of the Michaelis-Menten equation and its integrated form are discussed extensively. We will not delve deeply into those papers at the present time~ However, one or two points are worthy of special consideration. As one can see in Figs. 9 and 10, when equation 9 is obeyed (solid lines) there is initially an apparently linear segment and then a sharp break in the curve--the whole curve taking on a "hockey stick" shape. The apparently linear segment has often been assumed to be linear, because the assumption has been made that the enzyme is saturated. But this is a poor assumption because independent of the initial Co value the integrated form of the Michaelis-Menten equation always gives a pseudolinear portion over about two-thirds of the range or more. It is only pseudolinear since the derivative changes when the concentration changes, as evidenced by looking at the Michaelis-Menten equation itself. If one does assume that this pseudolinear segment is linear, and we symbolize the slope by k 0, then one can derive equation 12: indicates that if Vm and K,, remain constant, then a plot of the reciprocal of the slope of the pseudolinear portion will be linearly related to the reciprocal of the initial concentration or C o value. This shows why the classical concept of ethanol metabolism in man and animals is really incorrect. The apparently linear decline of alcohol blood levels will vary with the dose administered even if K,, and V m remain constant, and the slope will also be a function of the volume of distribution and sometimes of the absorption rate. However, as stated previously, when five doses of ethanol were taken at different times the values of K,,, V,,, and k 0 varied widely. Hence the classical concept that alcohol in a given individual is eliminated at a fixed rate independent of its concentration in the body was not supported by our studies. Also, one the value of K,, for the particular system is known, one can use equation 1 to calculate the percent saturation of the "enzyme system" at different C values of interest.
A CHECKLIST FOR POSSIBLE FUTURE PHARMACOKINETIC STUDIES
From my reading and experimental investigations, certain guidelines have emerged :
1. Preferably do intensive sampling after intravenous administration of several (preferably five or six) doses in at least one species of animal. The data from such studies provide much more information, when only one or two rats or dogs are used per dose, than when five to ten rats or dogs are given with only one or two doses of a drug.
2. After rapid intravenous injection, take initial samples very early after injection, such as at 1, 3, 5 min. Continue sampling until assay sensitivity is reached following all doses. Much of the apparent dose-dependent "first-order" kinetics in the literature was caused by estimating the first-order rate constant in a different concentration region after each dose. Also, extremely rapid uptake of many drugs by tissues has been "missed" since the first tissue samples were taken at 1 or 2 hr after injection.
3. Measure tissue levels as a function of both. time and dose in at least one species of animal such as the rat. The rapid intravenous route of administration is preferred and sampling should be as discussed above.
4. After oral administration of many rapidly absorbed drugs, blood samples should be taken as early as 10--20 rain alter administration in order to obtain data on the "up part'" of the plasma or blood concentration curve. Some drugs are absorbed by passive d(.~i~sion extremely rapidly in Jasting subjects. We have a distorted view since in most human studies the first blood sample has been taken l hr or later after administration. Recently, we found that the first blood sample, taken at 20 min after oral administration of sodium p-aminosalicylate in an aqueous solution to a fasting human subject, gave the highest plasma concentration of PAS.
5. To check quickly for tissue saturation effects, by measuring only plasma levels, perform a "'loading-dose'" experiment. Give, say, 5 mg/kg of drug by rapid intravenous injection and measure plasma concentrations of unchanged drug at 1, 5, and 10 min. Then give 10 mg/kg, and 1 hr later give 5 mg/kg, and measure the plasma concentration again at 1, 5, and 10 min after the 5 mg/kg dose. If the plasma levels are appreciably higher in the loading-dose experiment, this constitutes good evidence of some saturation phenomenon and usually it will be saturable tissue binding. With some drugs, the cited doses obviously would have to be drastically altered.
6. Be sure the analytical method used is specific for the unchanged drug and one or more metabolites and that the method has good sensitivity and reproducibility. After intravenous administration, it is preferable to be able to measure drug concentrations through at least two and preferably three or more log cycles on semilogarithmic graph paper. After oral administration, the assay method should be sensitive enough to follow the drug levels down to at least one-tenth or one-twentieth of the peak concentration. Samples should be collected so that this criterion can be met after each treatment, if possible. The literature is replete with erroneous half-lives of drugs since plasma levels were not measured for a long enough period of time. In drug availability studies, the calculation of "bioavailabitity" from measurement of the area under only one-half or two-thirds of the plasma concentration curve is just plain misleading.
7. Estimate elimination half-lives after different doses are administered to the same subject or animal in the same concentration range, not necessarily in the same time range.
